Abstract: The present invention provides a novel fusion protein of Flt3L and albumin and its use to increase the Flt3L half-life in vivo and to deliver Flt3L to immune cells in a subject to enhance alternative dendritic cell populations. Use of the fusion protein in combination with other chemotherapeutic, radiotherapeutic and immunotherapeutic methods are also provided.

Abstract: A luggage article includes a body that includes a zippered opening (15) that has at least one zipper arrangement having a zipper tape (14). The zipper arrangement includes one or more zipper sliders (16, 20) and one or more zipper pull-tabs (18, 22). Each of the one or more zipper sliders (16, 20) is joined to a respective one of the one or more zipper pull-tabs (18, 22). The luggage article includes a means (26) for holding the one or more pull-tabs in a substantially perpendicular arrangement to the zipper tape (14) of the zipper arrangement.

Abstract: Integrated chemical propellant and cold gas propulsion systems and methods are provided. A storage or fuel tank containing the chemical propellant is pressurized by a pressurant. The chemical propellant is selective passed to a propellant thruster through a first port of the storage tank and a propellant valve. The pressurant is selectively passed to a cold gas thruster through a second port of the storage tank and a cold gas valve. In addition, a pressurant tank can be provided. Pressurant contained within the pressurant tank can be selectively placed in communication with the pressurant contained within the storage tank via a pressurant valve, or can be selectively passed to the cold gas thruster through the cold gas thruster valve. Systems can also include bi-propellant thrusters, with a first and second chemical compounds and volumes of pressurant stored in first and second storage tanks respectively.

Abstract: A magnetic alignment system can include a primary annular magnetic alignment component and a secondary annular magnetic alignment component. The primary alignment component can include an inner annular region having a first magnetic orientation, an outer annular region having a second magnetic orientation opposite to the first magnetic orientation, and a non-magnetized central annular region disposed between the primary inner annular region and the primary outer annular region. The secondary alignment component can have a magnetic orientation with a radial component. Additional features, such as a rotational magnetic alignment component and/or an NFC coil and circuitry can be included.

Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

Abstract: In one embodiment, the application discloses a method for the treatment of cancer in a patient, the method comprises a vaccination of the patient with a vaccine, wherein the vaccine comprises an effective amount of mammalian pluripotent stem cells obtained from an embryonic source or obtained by reprogramming of somatic cells from the patient, wherein the vaccination comprising the step of administering a mammalian pluripotent stem cells to the patient in need thereof; and vaccine formulations for use in the treatment of cancer.

Abstract: Accessories that can add new functionality to an electronic device. These accessories can provide additional functionality that allow for the replacement of a physical object that would otherwise be carried in addition to and separate from the electronic device. These accessories can further provide improvements, such as a reduction in size or improvement in functionality over the physical object to be replaced.

Abstract: An article includes a zipper cover (14, 114) configured to conceal a zipper tape (18, 118) that is secured at a mouth of a zippered opening in a surface of the article and to longitudinally extend substantially parallel to the zipper tape. The zipper cover (14, 114) is attached to the surface of the article (10, 110) and is rotatable between a first orientation in which the zipper cover (14, 114) conceals the zipper tape (18, 118) and a second orientation in which the zipper cover exposes the zipper tape (18, 118) and allows a user to access the zippered opening. The zipper cover (14, 114) is magnetically securable to a surface (32, 132) of the zippered opening in the first orientation, and the zipper cover (14, 114) is magnetically securable against the surface (20, 120) of the article in the second orientation.

Abstract: A magnetic alignment system can include a case with a magnetic alignment component that is configured to align with a magnetic alignment component of a wireless charging device. The case can support a portable electronic device, such as a smart phone and include an NFC coil for communicating with the portable electronic device. The magnetic alignment component and the NFC coil can be provided as an assembly that is embedded within a body of the case in a manner that provides a low profile and improved aesthetic appearance.

Abstract: A portable electronic device can include a housing at least partially defining an internal volume. The device can include a venting module including a membrane, a porous member, and a support structure. The membrane and porous member can define a fluid path extending a width of the porous member and placing the internal volume in fluid communication with an ambient environment adjacent the housing. The support structure can be coupled to the porous member.

Abstract: The present invention provides a novel fusion protein of Flt3L and albumin and its use to increase the Flt3L half-life in vivo and to deliver Flt3L to immune cells in a subject to enhance alternative dendritic cell populations. Use of the fusion protein in combination with other chemotherapeutic, radiotherapeutic and immunotherapeutic methods are also provided.

Abstract: Microfluidic devices in which electrokinetic mechanisms move droplets of a liquid or particles in a liquid are described. The devices include at least one electrode that is optically transparent and/or flexible.

Abstract: A center pintle hub to be affixed to a base of a machine. The center pintle hub includes a base portion and a support portion. The base portion is formed to be affixed to the base. The support portion extends from the base portion and has a frusto-conical shape that can receive a center pintle shaft. The center pintle shaft can support a frame of the machine and provide rotation of the frame with respect to the base.

Abstract: Provided herein are compositions related to vaccines, e.g., influenza vaccines, including, peptide based vaccines, nucleic acid based vaccines, recombinant virus based vaccines, antibody based vaccines, and virus based vaccines. Also provided herein are methods related to vaccines, e.g., influenza vaccines, including methods of identifying epitopes for the vaccines, producing, formulating, and administering the vaccines.

Abstract: A microfluidic apparatus can comprise a dielectrophoresis (DEP) configured section for holding a first liquid medium and selectively inducing net DEP forces in the first liquid medium. The microfluidic apparatus can also comprise an electrowetting (EW) configured section for holding a second liquid medium on an electrowetting surface and selectively changing an effective wetting property of the electrowetting surface. The DEP configured section can be utilized to select and move a micro-object in the first liquid medium. The EW configured section can be utilized to pull a droplet of the first liquid medium into the second liquid medium.

Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

Abstract: Microfluidic devices in which electrokinetic mechanisms move droplets of a liquid or particles in a liquid are described. The devices include at least one electrode that is optically transparent and/or flexible.

Abstract: Embodiments include apparatuses, methods, and systems including a laser device having a 1×3 MMI coupler within a semiconductor layer. A front arm is coupled to the MMI coupler and terminated by a front reflector. In addition, a coarse tuning arm is coupled to the MMI coupler and terminated by a first back reflector for coarse wavelength tuning, a fine tuning arm is coupled to the MMI coupler and terminated by a second back reflector for fine wavelength tuning, and a SMSR and power tuning arm is coupled to the MMI coupler and terminated by a third back reflector. A gain region is above the front arm and above the semiconductor layer. Other embodiments may also be described and claimed.